Anti-Cardiolipin screen ELISA Kit

Anti-Cardiolipin (aCL) antibodies are autoantibodies directed against cardiolipin, a phospholipid component of the inner mitochondrial membrane that becomes immunogenic when bound to plasma proteins like β2-glycoprotein I. These antibodies are a key feature of antiphospholipid syndrome (APS), an autoimmune disorder characterized by arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia. Anti-cardiolipin antibodies can be of IgG, IgM, or IgA isotypes, and their persistence and titer are important in confirming diagnosis. The ELISA (enzyme-linked immunosorbent assay) is the standard laboratory method for detecting these antibodies, providing quantitative results that guide both diagnosis and risk stratification.

In the clinical setting, anti-cardiolipin ELISA is used to screen and diagnose APS, particularly in patients presenting with unexplained thrombosis or recurrent pregnancy complications. Positive results, especially for medium-to-high titers of IgG or IgM, support the diagnosis when combined with clinical criteria. Testing is also performed in patients with systemic lupus erythematosus (SLE), as aCL positivity increases the risk of thrombotic events. The assay helps clinicians assess thrombotic risk, guide anticoagulation therapy, and monitor antibody levels over time for prognostic purposes.

In research, anti-cardiolipin antibodies are studied as biomarkers of autoimmune thrombophilia, helping to elucidate the pathophysiology of APS and the role of phospholipid-reactive antibodies in vascular inflammation and clot formation. They are also used in longitudinal cohort studies to identify individuals at risk of thrombotic events and in clinical trials evaluating anticoagulant or immunomodulatory therapies. Anti-cardiolipin ELISA provides a standardized quantitative tool for both mechanistic and translational studies in autoimmune and thrombotic disorders.

This product is manufactured in Germany by Medipan GmbH.